Manjaro subcutaneous injection 15mg Ateos, manufactured by Eli Lilly Japan, contains Tirzepatide. This GIP and GLP-1 receptor agonist is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is provided as a 15mg 0.5mL 1 kit with YJ code 2499422G6026.
Manjaro subcutaneous injection 15mg Ateos
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).